Jinjia Group: Continued Investment in E-Cigarettes

Business by 2FIRSTS.ai

Mar.13.2024

Jinjia Group: Continued Investment in E-Cigarettes

Investor asked Jinjia Co. on investment platform if e-cigarettes are still in R&D. Jinjia Co. stated new tobacco business progressing as planned.

On March 12th, an investor asked Jinjia Group on an investor interaction platform if the company is still continuing to invest in the research and development of e-cigarettes. Jinjia Group (002191.SZ) responded that the company's new tobacco business is progressing orderly according to the established plan, striving to improve its operational performance and enhance its influence in the new tobacco field.

Also Read:

[1] Jinjia Group to Invest £500,000 ($634,000) for Establishment of Subsidiary in London

[2] Jinjia Holdings Expands Comprehensive Layout in New Tobacco Industry

[3] Creating Intelligent and Technological E-Cig Products: Jinjia Corporation's Vision

[4] No Collaboration between Jingjia Stock and Huada Beidou

#E-cigarettes #Asia #Open system e-cigarettes #China #Technology.#Products #E-cigarette #E-cigarettes and Tobacco #jinjia

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Mexican Senate Approves Nationwide Ban on E-Cigarettes and Vapes

Mexico’s Senate passed a reform to the General Health Law banning the production, importation, sale, and advertising of e-cigarettes and vape products nationwide. The bill passed with 76 votes in favor, 37 against, and one abstention.

Dec.12 by 2FIRSTS.ai

UK to Implement e-cigarette Product Tax and Stamp Plan from October 1, 2026

HMRC announces e-cigarette tax stamp plan to combat illicit trade starting October 1, 2026 alongside VPD policy enforcement.

Nov.27 by 2FIRSTS.ai

Hungary’s Continental Tobacco Launches New Slay Nicotine Pouch Brand in UK Targeting Female Consumers

Hungary’s Continental Tobacco Group has launched its Slay nicotine pouch brand in the UK, featuring compact, pastel-toned packaging and backed by a multi-million-pound investment and retail pilot programme to build its presence in the local market.

Dec.03 by 2FIRSTS.ai

U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency

The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.